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Fig. 1. Scatter plot of maternalsh~esize ~gainst maternal height. The
solid line represents the relatIOnship predicted by the regressIOn: y =
14.0 (SEE 1.1) . x -16.3 (SEE 1.8); F =151.42, df =1 and 213, P <
0.001; adjusted r> = 0.41. The dotted lines represent the 95%
confidence intervals of the regression line.
(r> =0.41) as that observed in Van Bogaert's study (r> =0.12).'
evertheless, there was only a modest tendency towards an
increased risk of caesarean delivery for mothers with smaller
shoe sizes and those with shorter statures (model 1, Table I) -
even selecting those cut-offs for shoe size (below size 7) and
stature (below 1.60 m) that displayed the strongest bivariate
associations with caesarean delivery (analyses not shown). The
statistical strength of these associations did increase after
controlling for maternal and neonatal factors that were
significantly associated with an increased risk of caesarean
delivery (BMI, previous caesarean delivery and macrosomia;
models 2 and 3, Table 1), but none achieved statistical
significance (models 2, 3 and 4, Table I). Instead, caesarean
deliveries were up to three times mOTe common among
mothers who were obese (> 29 kg/m') before delivery, while
mothers who had already had at least one previous caesarean
delivery were more than twice as likely to have another.
These findings suggest that neither shoe size nor stature
were important (or useful) risk factors for caesarean delivery in
this population. Either they had a limited predictive value for
pelvic (in)adequacy, or they were perceived as irrelevant by
those deciding whether to perform a caesarean delivery. Given
that only half of the obstetric records examined in the present
study contained records of maternal shoe size, and fewer of
these also contained maternal height measurements, it is likely
that the clinicians responsible for collecting this information
share the view of the World Health Organistation (WHO)
I collaborative panel, which recently concluded that stature did11mD not meet the screening criteria for assisted delivery.>
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PLANT STEROUSTEROLIN SUPPLEMENT USE IN
A COHORT OF SOUTH AFRICAN HIV-
INFECTED PATIENTS - EFFECTS ON
IMMUNOLOGICAL AND VIROLOGICAL
SURROGATE MARKERS
To the Editor: It has been demonstrated that micronutrient
supplementation m~y be an important prophylactic and
therapeutic measure for HIV-1-infected patients, and is
possibly one of the few potential interventions for low-income
countries.' In sub-Saharan countries facing the bulk of new
infections worldwide, the use of highly active antiretroviral
therapy (HAART) is out of reach of most patients because of
the cost in the private sector and the lack of provision of any
therapies by the health departments of these countries. In
recent years many groups have investigated the outcomes of
this infection in patients supplemented with vitamin B2 or
multivitamin supplementation including/excluding vitamin A
during pregnancy.' Some studies have shown that high doses
of vitamin B6 supplements were associated with improved
survival of patients, while zinc supplementation was associatec
with poorer survival.'
A supplement containing a mixture of plant sterols and
sterolins has been developed and investigated by our group in
the treatment of many diseases. This mixture has been shown
to have immune modulating activities - the addition of this
mixture to T-eells in vitro leads to the enhanced secretion of
interleukin 2 (IL2) and gamma interferon (INF_y)5~ and further
tests revealed that the mixture preferentially targets CD4 cells
of THl phenotype and leaves TH2 CD4 cells unaffected.' This
mixture was tested in a double-blind, placebo-eontroUed
manner as an adjuvant in patients with pulmonary tuberculosis
and it was shown to have a positive effect on disease recovery
in such patients.s The mixture was also tested in a double-
blind, placebo-eontrolled trial in healthy marathon runners
where it prevented exercise-induced inflammation and post-
event transient immune suppression! Furthermore, the
beneficial effects of this mixture in an animal model of
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Fig. 1. Median plaslllll viral loads in the patients in grOllp 3 (CD4 > SOD/id at
entry) showed a significant 1.48 log drop in viral load over 30 months. The
dllshed line indicates the trend of the actllal vallles (solid line) at each time
point.
The results of this pilot study open up new avenues that
need to be explored. Since the plant sterollsterolin mixture
was tested in an open-labelled manner in this group of infected
patients, new clinical trials must be initiated under strict
placebo-controlled trial conditions to prove efficacy. Such
studies are currently planned. However, considering the
median CD4 absolute count (median 349 ± 11 versus 275 ± 19
CD4/Jll blood, S) as well as the plasma viral load (5.06 ± 0.81
log versus 5.15 ± 0.84 log, 15).
The patients who were the most immunologically intact
(CD4> 500/Jll at baseline entry) showed significant changes
only in the virological parameters measured over a period of 39
months. These patients (N = 47) exhibited no Significant
change in the CD4 cell percentage (median 29 ± 0.9% versus
28.5 ± 4.7%, 5), no significant change in the median CD4 cell
absolute counts (646 ± 30 versus 639 ± 67 CD4/JlI blood,S)
but a significant decrease in the plasma viral load (4.59 ± 0.45
log versus 3.11 ± 0.38 log, P = 0.038; Fig. 1). The interesting
observation within this group is the fact that 7 patients within
this group (7/47,15%) had reached undetectable plasma viral
load (NASBA, detection limit of 200 copies/ml of plasma)
within 12 months of starting the study. 0 correlation was
found between the ability of such individuals to reach
undetectable viral loads within 12 months and either their
baseline viral loads or their baseline CD4 count. We can only
assume that this feature is linked to an innate immunological
feature that remains unclear at present. Such features may
include cytotoxic T cell (CTL) activity as described in long-term
non-progressors and non-infected sexual contacts of infected
patients,IO·1l or the ability to mount and maintain a beneficial
cytokine response l ' We have recently shown that patients who
have used the sterol/sterolin mixture for at least 12 months
exhibit a predominant THT cytokine response in vitro suggesting
that the mixture could possibly maintain a beneficial CD4 cell
response leading to effective CTL activity.' However, we have
not determined sequential CTL activity in the patients using
the mixture.
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retroviral disease (feline immunodeficiency virus (FIV)-infected
laboratory cats) has been reported previously aLamprecht
et al. - poster 11236, World AIDS Conference, 28 June - 3July
1998).
Our group has been investigating the immunological benefit
derived from the use of this natural mixture in a 6-year open-
labelled study of HIV-infected patients. The patients were
encouraged to participate in other clinical trials if they were
eligible for inclusion or to use appropriate antiviral treatment if
they could afford it. However, the results of the present report
include only the data derived from patients not on any other
forms of HIV therapy. To date, we have follow-up data from
123 patients over a period of 39 months. The patients were
stratified according to their baseline CD4 cell numbers on entry
and three groups were thus formed: patients with
CD4 < 200/)l1 at baseline (N = 10), those with CD4 200 - 500/)l1
iN =66), and patients with baseline CD4 > 500/)l1 (N = 47). All
oatients were followed up at monthly intervals for the first 3
months and thereafter at 4-monthly intervals. Body mass was
measured at each visit and any concomitant conditions
[including opportunistic infections) were noted and treated
1ppropriately. Prophylaxis against opportunistic infections was
prescribed according to accepted guidelines. Patients were
questioned at every visit as to their use of any other
supplements or medication - data on patients using any anti-
retroviral therapy were excluded from the present analysis.
The CD4 cell numbers were determined using flow cytometry
on whole blood. Plasma viral loads were assayed in stored
samples using automated nucleic acid sequence-based assay
. ASBA). Results were expressed as number of copies per
millilitre of plasma.
An independent statistician conducted the statistical analysis
and used the Statistical Analysis System (SAS) mixed
procedure analysis, testing for statistical differences between
baseline parameters and all follow-up values for each group.
Significance was set at
p < 0.05.
We have sequential data for 21 months for the group with
low CD4 numbers at baseline (CD4 < 200/JlI, N = 10). They
showed a statistically significant decline in the median
(± standard error of mean (SEM)) percentage and absolute
numbers of CD4 cells: 11 ± 1.6% and 134 ± 18 CD4/)l1 at
baseline to 7 ± 2.0% and 23 ± 21 CD4/)l1 at 21 months (P = om
and P = 0.001 respectively). During the same period of time,
although these patients lost the immune cells, they showed no
Significant increase or decline in the plasma viral load as
determined by ASBA: 4.23 ± 1.21 log at baseline and 4.60 at
21-month follow-up.
Follow-up data for the group with CD4 cells at baseline 200 -
500/)l1 (N = 66) are available for 39 months. Statistical analysis
of the data shows no significant change in the median CD4
percentage (19 ± 0.7% versus 18.5 ± 1.7 %; not significant S)),
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manner in which it impacts on the cells of the immune system,
it is not surprising that only the group of individuals who
begin the study with high CD4 cell counts would benefit if the
surrogate markers CD4 and viral loads are analysed and used
as endpoints of such a study. This mixture has no anti-
retroviral activity as determined by in vitro p24 production by
infected human lymphocytes (data not shown). Therefore, it
stands to reason that new studies must be directed at patients
who are newly diagnosed shortly after infection. However, the
group of individuals whose infection is long-standing may still
derive benefit in the absence of any therapy, as is the scenario
in Africa. In such patients perhaps the most relevant primary
endpoints (surrogate markers) of efficacy would include
mortality, rate/incidence of infections requiring intervention,
hospitalisation, etc. We have already shown that such patients,
despite the loss of CD4 cell numbers over the study period,
maintain their body weight, a marker that would indirectly
indicate disease progression.
This study also introduces the possibility of investigating the
use of this natural immune-modulating mixture together with a
simple and less expensive regimen of enhanced monoth~rapy
(such as didanosine and hydroxyurea) or pulse therapy using
combination therapy when required to control viral replication.
This scenario is possibly the most appropriate for Africa where
the costs of such drugs are prohibitive to the majority of
infected patients.
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USE OF ALTERNATIVE MEDICINE BY PATIENTS
WITH NEUROLOGICAL DISEASE
To the Editor: After publication of a paper on alternative
medicine (AM) in this Journal in 1999,' several further cases of
inappropriate management by AM practitioners were seen at
Wentworth Hospital. This observation prompted a study to
determine the extent and type of AM used by an inpatient
population.
Patient use of AM was determined by means of a
questionnaire. Questions included the type of AM use, mode 0
therapy, cost, and explanation given by the AM practitioner.
The findings were compared with final conventional medicine
(CM) diagnosis and treatability of the condition.
There were three groups of patients: those who had sought
the help of AM practitioners (N = 32), those who did not (N = 41)
and cases where information was not available (N = 7).
In the AM group all but 1 patient attended a traditional
healer; the majority of these patients were given oral
medication. Eleven of these 31 patients (35%) did not know the
cost of treatment as a relative had paid the fees. Two patients
were treated for free. The fees charged for the remaining 18
respondents ranged from R20 - R2 000, to a goat, to an ox plus
a goat. While this study did not address the financial status of
the patients, virtually all those from a disadvantaged
background are classified as 'HI' individuals by the hospital.
Such patients are charged an all-inclusive fee of Rl34 per
month of hospital stay_ The majority of these patients did not
pay hospital fees at all. The diagnoses given to the patients by
the AM practitioners and the corresponding CM diagnoses are
listed in Table 1.
Sixty-three per cent of the AM patients said that they were
not given an explanation of the'findings. This observation is
